Tenaya Therapeutics Inc

NASDAQ TNYA

Data sourced from

and

Download Data

Tenaya Therapeutics Inc Accounts Receivable Turnover Ratio 3 year CAGR for the Trailing 12 Months (TTM) ending June 30, 2023

Tenaya Therapeutics Inc Accounts Receivable Turnover Ratio 3 year CAGR is NA for the Trailing 12 Months (TTM) ending June 30, 2023. The accounts receivable turnover ratio measures the efficiency of a company in collecting payments from its customers. It is calculated by dividing the company's revenue by its accounts receivable. This ratio provides insight into how quickly a company collects outstanding funds owed to it. A higher turnover ratio implies that the company efficiently converts credit sales into cash, while a lower ratio may indicate delays in collecting payments or potential issues with credit management. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Tenaya Therapeutics Inc Accounts Receivable Turnover Ratio for the Trailing 12 Months (TTM) ending March 31, 2023 was 0.00.

NASDAQ: TNYA

Tenaya Therapeutics Inc

CEO	Mr. Faraz Ali M.B.A.
IPO Date	July 30, 2021
Location	United States
Headquarters	171 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees	140
Sector	Healthcare
Industry	Biotechnology

Description

Tenaya Therapeutics, Inc., a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage. It also develops an adeno-associated virus-based gene therapy designed to deliver the dworf gene for patient with dilated cardiomyopathy; and reprogramming program for heart failure due to prior myocardial infarction. Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

Key trends